Aligos Therapeutics

(NASDAQ) ALGS

Current Price$6.23

Market Cap$39.85M

Since IPO (2020)-98%

5 Year-99%

1 Year+32%

1 Month-19%

Aligos Therapeutics Financials at a Glance

Market Cap

$39.85M

Revenue (TTM)

$4.71M

Net Income (TTM)

$90.32M

EPS (TTM)

$-8.70

P/E Ratio

-0.75

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$6.23

Volume

5,697

Open

$6.35

Price

$6.23

Volume

5,697

Open

$6.35

Previous Close

$6.44

Daily Range

$6.23 - $6.57

52-Week Range

$4.60 - $13.69

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$6.23

Volume

5,697

Open

$6.35

Previous Close

$6.44

Daily Range

$6.23 - $6.57

52-Week Range

$4.60 - $13.69

ALGS News

Why Aligos Therapeutics Stock Crumbled Today

Eric VolkmanJan 6, 2022

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aligos Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Lawrence M. Blatt, PhD, MBA

Website

www.aligos.com

Headquarters

South San Francisco, CA 94080, US

ALGS Financials

Key Financial Metrics (TTM)

Gross Margin

89%

Operating Margin

-20%

Net Income Margin

-19%

Return on Equity

-122%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-1.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$39.85M

Shares Outstanding

6.19M

Volume

5.70K

Avg. Volume

177.45K

Financials (TTM)

Gross Profit

$1.26M

Operating Income

$87.98M

EBITDA

$87.06M

Operating Cash Flow

$82.50M

Capital Expenditure

$437.00K

Free Cash Flow

$82.94M

Cash & ST Invst.

$77.84M

Total Debt

$5.25M

Aligos Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$2.83M

+810.0%

Gross Profit

$2.83M

+810.0%

Gross Margin

100.00%

N/A

Market Cap

$39.85M

N/A

Market Cap/Employee

$569.28K

N/A

Employees

N/A

Net Income

$23.04M

-153.5%

EBITDA

$26.58M

-41.9%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$50.73M

-61.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$659.00K

-85.0%

Short Term Debt

$3.69M

+5.9%

Return on Assets

-1.40%

N/A

Return on Invested Capital

-2.32%

N/A

Free Cash Flow

$23.20M

-10.7%

Operating Cash Flow

$23.13M

-10.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

INMBINmune Bio, Inc.

INMBINmune Bio, Inc.$1.41-1.40%

FGENFibroGen, Inc.

FGENFibroGen, Inc.$9.07-1.63%

OKUROnKure Therapeutics, Inc.

OKUROnKure Therapeutics, Inc.$3.53-9.72%

SKYESkye Bioscience, Inc.

SKYESkye Bioscience, Inc.$0.87+0.85%

XFORX4 Pharmaceuticals, Inc.

XFORX4 Pharmaceuticals, Inc.$4.53+2.26%

BRNSBarinthus Biotherapeutics plc

BRNSBarinthus Biotherapeutics plc$0.67+0.01%

KZRKezar Life Sciences, Inc.

KZRKezar Life Sciences, Inc.$7.29+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$16.37+0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.89+0.01%

ODYSOdysight.ai

ODYSOdysight.ai$5.46+0.22%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.23-0.01%

DGXXDigi Power X

DGXXDigi Power X$7.73+0.17%

CRCLCircle Internet Group

CRCLCircle Internet Group$128.37+0.13%

TSDDGraniteShares ETF Trust - GraniteShares 2x Short Tsla Daily ETF

TSDDGraniteShares ETF Trust - GraniteShares 2x Short Tsla Daily ETF$7.08-0.05%

Questions About ALGS

What is the current price of Aligos Therapeutics?

Aligos Therapeutics is trading at $6.23 per share.

What is the 52-week range for Aligos Therapeutics?

Over the past 52 weeks, Aligos Therapeutics has traded between $4.60 and $13.69.

How much debt does Aligos Therapeutics have?

As of the most recent reporting period, Aligos Therapeutics reported total debt of $4.35M.

How much cash does Aligos Therapeutics have on hand?

Aligos Therapeutics reported $30.15M in cash and cash equivalents in its most recent financial results.

What is Aligos Therapeutics’s dividend yield?

Aligos Therapeutics does not currently have a dividend yield.

Aligos Therapeutics

Aligos Therapeutics Financials at a Glance

ALGS News

Why Aligos Therapeutics Stock Crumbled Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Aligos Therapeutics

ALGS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Aligos Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ALGS

What is the current price of Aligos Therapeutics?

What is the 52-week range for Aligos Therapeutics?

How much debt does Aligos Therapeutics have?

How much cash does Aligos Therapeutics have on hand?

What is Aligos Therapeutics’s dividend yield?

Premium Investing Services